Targeting poly(ADP-ribosyl)ation: a promising approach in cancer therapy

被引：86

作者：

Haince, JF

Rouleau, M

Hendzel, MJ

Masson, JY

Poirier, GG ^{[1
]}

机构：

[1] Univ Laval, Hlth & Environm Unit, Laval Univ Hosp Res Ctr, CHUQ,Fac Med, Quebec City, PQ G1K 7P4, Canada

[2] Univ Alberta, Fac Med, Dept Oncol, Edmonton, AB T6G 2M7, Canada

[3] CHUQ, Hotel Dieu Quebec, Quebec City, PQ, Canada

来源：

TRENDS IN MOLECULAR MEDICINE | 2005年 / 11卷 / 10期

基金：

加拿大健康研究院;

关键词：

D O I：

10.1016/j.molmed.2005.08.003

中图分类号：

Q5 [生物化学]; Q7 [分子生物学];

学科分类号：

071010 ; 081704 ;

摘要：

Recent progress in the field of DNA repair has demonstrated that transient inhibition of DNA damage detection or repair using potent poly(ADP-ribose) polymerase (PARP) inhibitors could improve the efficacy of cancer treatments. Although more study is needed, recent publications lead to optimism that the inhibition of poly(ADP-ribose) synthesis could selectively kill cancer cells when used to treat tumours with defective BRCA proteins. These reports and others shed some light on the DNA damage signalling and repair processes involving PARPs. However, a better understanding of the molecular mechanisms regulated by poly(ADP-ribose) metabolism will be essential before optimism can be replaced by clinical realization.

引用

收藏

页码：456 / 463

页数：8

相关论文

共 67 条

[1]

Abdelkarim GE, 2001, INT J MOL MED, V7, P255

[2] BAL is a novel risk-related gene in diffuse large B-cell lymphomas that enhances cellular migration [J].

Aguiar, RCT ;

Yakushijin, Y ;

Kharbanda, S ;

Salgia, R ;

Fletcher, JA ;

Shipp, MA .

BLOOD, 2000, 96 (13) :4328-4334

[3] The PARP superfamily [J].

Amé, JC ;

Spenlehauer, C ;

de Murcia, G .

BIOESSAYS, 2004, 26 (08) :882-893

[4] DNA double-strand breaks associated with replication forks are predominantly repaired by homologous recombination involving an exchange mechanism in mammalian cells [J].

Arnaudeau, C ;

Lundin, C ;

Helleday, T .

JOURNAL OF MOLECULAR BIOLOGY, 2001, 307 (05) :1235-1245

[5] Involvement of poly(ADP-ribose) polymerase-1 and XRCC1/DNA ligase III in an alternative route for DNA double-strand breaks rejoining [J].

Audebert, M ;

Salles, B ;

Calsou, P .

JOURNAL OF BIOLOGICAL CHEMISTRY, 2004, 279 (53) :55117-55126

[6] DNA damage response as a candidate anti-cancer barrier in early human tumorigenesis [J].

Bartkova, J ;

Horejsi, Z ;

Koed, K ;

Krämer, A ;

Tort, F ;

Zieger, K ;

Guldberg, P ;

Sehested, M ;

Nesland, JM ;

Lukas, C ;

Orntoft, T ;

Lukas, J ;

Bartek, J .

NATURE, 2005, 434 (7035) :864-870

[7] Poly(ADP-ribosyl)ation inhibitors:: Promising drug candidates for a wide variety of pathophysiologic conditions [J].

Beneke, S ;

Diefenbach, J ;

Bürkle, A .

INTERNATIONAL JOURNAL OF CANCER, 2004, 111 (06) :813-818

[8] Regulation of poly(ADP-ribose) metabolism by poly(ADP-ribose) glycohydrolase: where and when? [J].

Bonicalzi, ME ;

Haince, JF ;

Droit, A ;

Poirier, GG .

CELLULAR AND MOLECULAR LIFE SCIENCES, 2005, 62 (7-8) :739-750

[9] Potentiation of anti-cancer agent cytotoxicity by the potent poly(ADP-ribose) polymerase inhibitors NU1025 and NU1064 [J].

Bowman, KJ ;

White, A ;

Golding, BT ;

Griffin, RJ ;

Curtin, NJ .

BRITISH JOURNAL OF CANCER, 1998, 78 (10) :1269-1277

[10] Radio sensitization of human and rodent cell lines by INO-1001, a novel inhibitor of poly(ADP-ribose) polymerase [J].

Brock, WA ;

Milas, L ;

Bergh, S ;

Lo, R ;

Szabó, C ;

Mason, KA .

CANCER LETTERS, 2004, 205 (02) :155-160

← 1 2 3 4 5 6 7 →